How many drugs treat Neurogenic bladder?

Drug Landscape tracks 3 marketed treatments for Neurogenic bladder (deduplicated by molecule). 0 Phase 3 candidates and 0 Phase 2 candidates are in the pipeline.

How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/neurogenic-bladder.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Neurogenic bladder — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Neurogenic bladder (disease) competitive landscape: 3 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

3 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Neurogenic bladder, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Nuceiva	BOTULINUM TOXIN TYPE A	GlaxoSmithKline K.K.	Acetylcholine Release Inhibitor [EPC]	Synaptosomal-associated protein 25	2019-01-01
Ditropan Xl	OXYBUTYNIN	Hisamitsu Pharmaceutical Co., Inc.	Cholinergic Muscarinic Antagonist	Muscarinic acetylcholine receptor M3	1975-01-01
Oxytrol	Oxytrol	Jewish General Hospital		Cytochrome P450 2C19, 5-hydroxytryptamine receptor 2B, D(3) dopamine receptor

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

· 1 drug in Neurogenic bladder
GlaxoSmithKline K.K. · 1 drug in Neurogenic bladder
Hisamitsu Pharmaceutical Co., Inc. · 1 drug in Neurogenic bladder
Jewish General Hospital · 1 drug in Neurogenic bladder

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Neurogenic bladder:

Cite this brief

Drug Landscape (2026). Neurogenic bladder — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/neurogenic-bladder. Accessed 2026-06-10.

Neurogenic bladder full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing